PORTFOLIO NEWS Surrozen Appoints Charles Williams as Chief Financial Officer October 30, 2020 Read More » Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results October 29, 2020 Read More » Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers October 24, 2020 Read More » NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4 October 19, 2020 Read More » ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program October 19, 2020 Read More » eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer October 15, 2020 Read More » Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update October 14, 2020 Read More » A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics October 6, 2020 Read More » Arcus Biosciences: Jennifer Jarrett Returns as Chief Operating Officer October 1, 2020 Read More » Carmot Therapeutics Expands Leadership Team and Closes $47M Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies September 30, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Next »
Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results October 29, 2020 Read More »
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers October 24, 2020 Read More »
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4 October 19, 2020 Read More »
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program October 19, 2020 Read More »
Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update October 14, 2020 Read More »
A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics October 6, 2020 Read More »
Carmot Therapeutics Expands Leadership Team and Closes $47M Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies September 30, 2020 Read More »
